Literature DB >> 20350533

DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma.

Lei Wang1, Hiroshi Nishihara, Taichi Kimura, Yasutaka Kato, Mishie Tanino, Mitsufumi Nishio, Masato Obara, Tomoyuki Endo, Takao Koike, Shinya Tanaka.   

Abstract

DOCK2; a member of the CDM protein family, regulates cell motility and cytokine production through the activation of Rac in mammalian hematopoietic cells and plays a pivotal role in the modulation of the immune system. Here we demonstrated the alternative function of DOCK2 in hematopoietic tumor cells, especially in terms of its association with the tumor progression. Immunostaining for DOCK2 in 20 cases of human B cell lymphoma tissue specimens including diffuse large B cell lymphoma and follicular lymphoma revealed the prominent expression of DOCK2 in all of the lymphoma cells. DOCK2-knockdown (KD) of the B cell lymphoma cell lines, Ramos and Raji, using the lentiviral shRNA system presented decreased cell proliferation compared to the control cells. Furthermore, the tumor formation of DOCK2-KD Ramos cell in nude mice was significantly abrogated. Western blotting analysis and pull-down assay using GST-PAK-RBD kimeric protein suggested the presence of DOCK2-Rac-ERK pathway regulating the cell proliferation of these lymphoma cells. This is the first report to clarify the prominent role of DOCK2 in hematopoietic malignancy. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350533     DOI: 10.1016/j.bbrc.2010.03.148

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Proteomics analysis of the ezrin interactome in B cells reveals a novel association with Myo18aα.

Authors:  Ken Matsui; Neetha Parameswaran; Nayer Bagheri; Belinda Willard; Neetu Gupta
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

2.  Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis.

Authors:  H Zhao; W Cai; S Su; D Zhi; J Lu; S Liu
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

3.  Dedicator of Cytokinesis 2 (DOCK2) Deficiency Attenuates Lung Injury Associated with Chronic High-Fat and High-Fructose Diet-Induced Obesity.

Authors:  Guoqing Qian; Oluwaseun Adeyanju; Christudas Sunil; Steven K Huang; Shi-You Chen; Torry A Tucker; Steven Idell; Xia Guo
Journal:  Am J Pathol       Date:  2021-11-10       Impact factor: 4.307

4.  DOCK2 Sets the Threshold for Entry into the Virtual Memory CD8+ T Cell Compartment by Negatively Regulating Tonic TCR Triggering.

Authors:  Vinay S Mahajan; Ezana Demissie; Faisal Alsufyani; Sudha Kumari; Grace J Yuen; Vinayak Viswanadham; Andrew Huang; Johnson Q Tran; James J Moon; Darrell J Irvine; Shiv Pillai
Journal:  J Immunol       Date:  2019-11-18       Impact factor: 5.422

5.  Integrated genomic analysis of survival outliers in glioblastoma.

Authors:  Sen Peng; Harshil Dhruv; Brock Armstrong; Bodour Salhia; Christophe Legendre; Jeffrey Kiefer; Julianna Parks; Selene Virk; Andrew E Sloan; Quinn T Ostrom; Jill S Barnholtz-Sloan; Nhan L Tran; Michael E Berens
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

6.  Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Toru Furukawa; Yuko Kuboki; Etsuko Tanji; Shoko Yoshida; Takashi Hatori; Masakazu Yamamoto; Noriyuki Shibata; Kyoko Shimizu; Naoyuki Kamatani; Keiko Shiratori
Journal:  Sci Rep       Date:  2011-11-18       Impact factor: 4.379

7.  Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.

Authors:  Md Kamrul Hasan; Jian Yu; George F Widhopf; Laura Z Rassenti; Liguang Chen; Zhouxin Shen; Steven P Briggs; Donna S Neuberg; Thomas J Kipps
Journal:  Blood       Date:  2018-04-20       Impact factor: 25.476

8.  DOCK2: A novel FLT3/ITD leukemia drug target.

Authors:  Min Wu; Donald Small; Amy S Duffield
Journal:  Oncotarget       Date:  2017-09-30

9.  DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.

Authors:  M Wu; M Hamaker; L Li; D Small; A S Duffield
Journal:  Leukemia       Date:  2016-10-17       Impact factor: 11.528

10.  High expression of DOCK2 indicates good prognosis in acute myeloid leukemia.

Authors:  Ning Hu; Yifan Pang; Hongmian Zhao; Chaozeng Si; Hui Ding; Li Chen; Chao Wang; Tong Qin; Qianyu Li; Yu Han; Yifeng Dai; Yijie Zhang; Jinlong Shi; Depei Wu; Xinyou Zhang; Zhiheng Cheng; Lin Fu
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.